Direct to Consumer Advertising and Prescription Choice

Published on Apr 20, 2005in Journal of Industrial Economics1.194
· DOI :10.2139/SSRN.700921
Toshiaki Iizuka13
Estimated H-index: 13
(Aoyama Gakuin University),
Ginger Zhe Jin30
Estimated H-index: 30
(UMD: University of Maryland, College Park)
This paper examines the effect of direct-to-consumer advertising (DTCA) of prescription drugs on doctors' choice of drug brands. Using antihistamines as an example, we show that DTCA has little effect on the choice of brand despite the massive DTCA expenditure incurred in this class. In contrast, promotional activities directed toward physicians have larger and longer lasting effects. These results, together with the market-expanding results shown in Iizuka and Jin (2005), suggest that DTCA is effective in increasing the aggregate demand per therapeutic class but does not affect doctor choice of prescription within a class. Therefore, DTCA may be viewed as a public good for all drugs in the same class.
📖 Papers frequently viewed together
1 Author (Marta Wosinska)
Cited By16
Exploiting the discontinuity in advertising along the borders of television markets, I estimate that television advertising of prescription antidepressants exhibits significant positive spillovers on rivals’ demand. I apply this identification in a demand model, where estimated parameters indicate significant and persistent spillovers driven by market expansion. Using the demand estimates to calibrate a stylized supply model, I explore the consequences of the positive spillovers on firm advertis...
With the Hatch-Waxman Act of 1984, the FDA included an unchallengeable exclusivity period for newly approved drugs, independent of patents. This potentially generates an incentive for firms to strategically delay the introduction of new versions (reformulations) of drugs until just before patent expiration of the original drug. This way the reformulated drug competes mainly with newly introduced generics of the original drug. If instead, the reformulated drug was to be introduced well before the...
#1W. David Bradford (UGA: University of Georgia)H-Index: 27
#2Andrew N. Kleit (PSU: Pennsylvania State University)H-Index: 22
Nonsteroidal anti‐inflammatory drugs (NSAIDs) are one of the most important classes of prescription drugs used by primary care physicians to manage pain. The NSAID class of products has a somewhat controversial history, around which a complex regulatory and informational environment has developed. This history includes a boxed warning mandated by the Food and Drug Administration (FDA) for all NSAIDs in 2005. We investigate the impact that various information shocks have had on the use of prescri...
#1Hemant Bamoriya (Acropolis Institute of Technology & Research)H-Index: 3
The Indian Pharma market is highly fragmented & nature of competition is intense. Further, in modern times influencing doctors’ prescription decision has become very complex as there is little systematic knowledge about factors affecting the doctors’ prescription behaviour and the weight of individual factor. This study aims to demystify this complex prescription behaviour of doctors, through examining the above mentioned factors. For this purpose, a focus group study will be followed by a quant...
Context: This article explores the relative impact of marketing information and FDA regulatory actions in the market for prescription drugs. We examine how direct to consumer advertising (DTCA) and FDA issued precautions and boxed warnings together affect young patients' visits with physicians and active prescriptions for anti-depressants. Methods: We aggregate 10 years (1998-2006) of detailed electronic medical record data on 9344 patients (254,810 patient-months) between the ages of 5 and 25, ...
Ce papier propose un modele de differenciation horizontale afin d'analyser la concurrence en promotion sur le marche pharmaceutique. La promotion pharmaceutique cible a la fois le medecin et le patient. Neanmoins, la nature de ces strategies differe : la promotion orientee vers le consommateur (POC) eleve la demande de marche et la promotion orientee vers le medecin (POM) augmente la part de marche. Dans un cadre theorique, nous obtenons un resultat principal. D'une part, la profitabilite de la ...
#1Rosemary J. Avery (Cornell University)H-Index: 20
#2Matthew Eisenberg (CMU: Carnegie Mellon University)H-Index: 12
Last. Kosali Simon (IU: Indiana University)H-Index: 35
view all 3 authors...
We examine whether exposure to direct-to-consumer advertising (DTCA) for antidepressant drugs affects individual use of these medications among those suffering from depression. Prior studies have almost exclusively relied on making connections between national or market-level advertising volume/expenditures and national or individual-level usage of medications. This is the first study to: estimate the impact of individual-level exposure to DTCA on individual-level use of antidepressants; estimat...
#1Erin Cavusgil (UM: University of Michigan)H-Index: 23
#2Roger J. Calantone (SPbU: Saint Petersburg State University)H-Index: 96
Marketing managers continually struggle with how to maximize the effects of an integrated marketing communications strategy. The growing number of available communication outlets, as well as highly varying competitive landscapes, adds further complexity to this challenge. This empirical study examines the differential impact within a pharmaceutical market therapeutic category where both “push” and “pull” communication strategies operate on consumers and gatekeepers alike, in an atmosphere of unr...
#1Wilfred Amaldoss (Duke University)H-Index: 21
#2Chuan He (CU: University of Colorado Boulder)H-Index: 9
Consumers cannot purchase a prescription drug without a prescription from a physician, yet many prescription drugs are promoted to consumers with the help of direct-to-consumer (DTC) advertising. In this paper, we propose and test a competitive model of DTC advertising. We find that the brand specificity of DTC advertising can have an inverted U-shaped relationship with detailing, DTC advertising, and profits. Furthermore, an increase in the cross-price sensitivity between competing prescription...
#1Ernst R. BerndtH-Index: 11
#2Julie M. DonohueH-Index: 3
Last. Thomas JeffersonH-Index: 1
view all 5 authors...
*Berndt is the Louis B. Seley Professor of Applied Economics at the Massachusetts Institute of Technology, Sloan School of Management, and Director of the National Bureau of Economic Research, Program on Technological Change and Productivity Measurement. Donohue is Assistant Professor of Health Policy and Management at the University of Pittsburgh Graduate School of Public Health. Berndt acknowledges general funding support from the MIT Center for Biomedical Innovation., while Donohue acknowledg...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.